Literature DB >> 19679215

Viscerotropic disease following yellow fever vaccination in Peru.

Alvaro Whittembury1, Gladys Ramirez, Herminio Hernández, Alba Maria Ropero, Steve Waterman, María Ticona, Margo Brinton, Jorge Uchuya, Mark Gershman, Washington Toledo, Erin Staples, Clarense Campos, Mario Martínez, Gwong-Jen J Chang, Cesar Cabezas, Robert Lanciotti, Sherif Zaki, Joel M Montgomery, Thomas Monath, Edward Hayes.   

Abstract

Five suspected cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) clustered in space and time following a vaccination campaign in Ica, Peru in 2007. All five people received the same lot of 17DD live attenuated yellow fever vaccine before their illness; four of the five died of confirmed YEL-AVD. The surviving case was classified as probable YEL-AVD. Intensive investigation yielded no abnormalities of the implicated vaccine lot and no common risk factors. This is the first described space-time cluster of yellow fever viscerotropic disease involving more than two cases. Mass yellow fever vaccination should be avoided in areas that present extremely low risk of yellow fever.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679215     DOI: 10.1016/j.vaccine.2009.07.082

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.

Authors:  Richard W Douce; Diana Freire; Betzabe Tello; Gavino A Vásquez
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

2.  Assessing the risk of international spread of yellow fever virus: a mathematical analysis of an urban outbreak in Asuncion, 2008.

Authors:  Michael A Johansson; Neysarí Arana-Vizcarrondo; Brad J Biggerstaff; Nancy Gallagher; Nina Marano; J Erin Staples
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

3.  Genomic and phylogenetic characterization of Brazilian yellow fever virus strains.

Authors:  Marcio R T Nunes; Gustavo Palacios; Jedson F Cardoso; Livia C Martins; Edivaldo C Sousa; Clayton P S de Lima; Daniele B A Medeiros; Nazir Savji; Aaloki Desai; Sueli G Rodrigues; Valeria L Carvalho; W Ian Lipkin; Pedro F C Vasconcelos
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

Review 4.  Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.

Authors:  S Elizabeth Williams; Nicola P Klein; Neal Halsey; Cornelia L Dekker; Roger P Baxter; Colin D Marchant; Philip S LaRussa; Robert C Sparks; Jerome I Tokars; Barbara A Pahud; Laurie Aukes; Kathleen Jakob; Silvia Coronel; Howard Choi; Barbara A Slade; Kathryn M Edwards
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

5.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

Review 6.  Experimental therapies for yellow fever.

Authors:  Justin G Julander
Journal:  Antiviral Res       Date:  2012-12-10       Impact factor: 5.970

7.  Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.

Authors:  Thomas P Monath
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

8.  Incubation periods of Yellow fever virus.

Authors:  Michael A Johansson; Neysarí Arana-Vizcarrondo; Brad J Biggerstaff; J Erin Staples
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

Review 9.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Stephen J Seligman; James S Robertson; Bruno Guy; Edward B Hayes; Richard C Condit; Jean Louis Excler; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2014-10-27       Impact factor: 3.641

Review 10.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.